Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al.

MLA

Curtis, Jeffrey R., et al. “Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et Al.” Arthritis & Rheumatology (Hoboken, N.J.), vol. 69, no. 4, Apr. 2017, pp. 863–65. EBSCOhost, https://doi.org/10.1002/art.39981.

APA

Curtis, J. R., Wright, G. C., Strand, V., Davis, C. S., Hitraya, E., & Sasso, E. H. (2017). Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. Arthritis & Rheumatology (Hoboken, N.J.), 69(4), 863–865. https://doi.org/10.1002/art.39981

Chicago

Curtis, Jeffrey R, Grace C Wright, Vibeke Strand, Charles S Davis, Elena Hitraya, and Eric H Sasso. 2017. “Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et Al.” Arthritis & Rheumatology (Hoboken, N.J.) 69 (4): 863–65. doi:10.1002/art.39981.